HCV Immunogenic Composition Using Conserved T-Cell Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective compositions and methods for inducing immune responses to Hepatitis C virus (HCV) that provide broad protection across multiple genotypes, as existing vaccines may not adequately address chronic infections and liver-related complications.
Innovation Solution
Development of an immunogenic composition comprising HCV heterodimeric polypeptides, E1 and E2 polypeptides, or T-cell epitope polypeptides conserved across HCV genotypes, combined with a pharmaceutically acceptable excipient, to induce immune responses, including CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing vaccines are used, then some immune response is induced, but broad protection across multiple HCV genotypes is not achieved
Solution Approach 1:
The vaccine composition uses conserved HCV epitopes that are universally recognized across multiple HCV genotypes (1-7). The T-cell epitope polypeptides are designed to elicit immune responses that are effective against diverse HCV strains, making the vaccine universally protective rather than genotype-specific.
Solution Approach 2:
The invention changes the immunogenic parameters by selecting specific conserved epitopes from HCV proteins (core, NS3, NS4, NS5) that maintain high sequence conservation across genotypes. This parameter selection ensures the vaccine targets invariant regions of the virus, achieving broad genotype coverage.
2Adaptability or versatility
If T-cell epitopes from multiple HCV proteins are included, then broad immune response is elicited, but composition complexity increases
Solution Approach 1:
The vaccine composition is segmented into distinct functional components: T-cell epitope polypeptides from different HCV proteins (core, NS3, NS4, NS5), B-cell epitope polypeptides (E1/E2), and adjuvants. Each segment targets specific immune pathways, allowing systematic construction of a comprehensive immune response without overwhelming complexity.
Solution Approach 2:
The invention merges multiple epitope sequences into single T-cell epitope polypeptide constructs. These fused polypeptides contain multiple conserved T-cell epitopes from different HCV proteins, combining their immunogenic potential into unified molecular entities that simplify formulation while maintaining broad coverage.
3Adaptability or versatility
If conserved epitopes across all HCV genotypes are targeted, then cross-neutralizing antibodies are induced, but manufacturing precision requirements increase
Solution Approach 1:
The vaccine focuses on specific local regions (conserved epitopes) within HCV proteins that exhibit high sequence identity across genotypes. By targeting these locally conserved regions rather than entire proteins, the design achieves cross-neutralizing activity while reducing the impact of sequence variations in other regions.
Solution Approach 2:
The T-cell epitope polypeptides are designed as synthetic copies of conserved HCV sequences. These recombinant polypeptides replicate the immunogenic properties of natural HCV epitopes without requiring live virus or complex viral particle production, simplifying manufacturing while maintaining epitope accuracy.
Data Source
AI summary
The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a “T-cell epitope polypeptide” or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4+ and CD8+ T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.